Frankfurt
25.03.26 | 08:03
0,161 Euro
-1,82 % -0,003
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,174 | 0,189 | 20:36 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.03. | Mauna Kea Technologies Updates Its Financial Calendar | 225 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today... ► Artikel lesen | |
| 23.02. | Mauna Kea Technologies Accelerates International Expansion with New Regulatory Clearances in Switzerland and the United Kingdom | 483 | Business Wire | These clearances enable the commercialization of Cellvizio in two major markets and accelerate the Group's international expansion First order for the next-generation Cellvizio (Gen 3) platform... ► Artikel lesen | |
| 10.02. | Mauna Kea Technologies Announces CE MDR Certification For Cellvizio and Its Associated Probes | 402 | Business Wire | A major regulatory milestone in the European commercial expansion strategy Mauna Kea Technologies is the only endomicroscopy company to obtain this certification under the new European regulation
Regulatory... ► Artikel lesen | |
| 06.02. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 424 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 04.02. | Mauna Kea Technologies Announces New Commercial Organization to Accelerate Growth Outside the United States | 505 | Business Wire | Building on Strong 2025 Momentum with Accelerated Sales Growth in Pancreatic Cysts €1M Milestone for CellTolerance Appointment of Benoit Chardon as Fractional Chief Commercial Officer to Lead... ► Artikel lesen | |
| 26.01. | Mauna Kea Technologies Announces Initiation of Coverage by Allinvest Securities | 268 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) announces today... ► Artikel lesen | |
| 21.01. | Mauna Kea Technologies Announces Its 2026 Financial Calendar Highlighted by Its Participation in Several Investor Forums | 644 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today... ► Artikel lesen | |
| MAUNA KEA TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 15.01. | Mauna Kea Technologies Reports Strong Q4 2025 Sales Driven by Accelerated Growth in the U.S. | 1.251 | Business Wire | Q4 2025 revenue up 19% on a reported basis (+29% excluding currency effects CER) Sales in the United States up 65% (+82% at CER) after three consecutive quarters of acceleration (+11%, +23%,... ► Artikel lesen | |
| 09.01. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 341 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 05.12.25 | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 422 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 03.12.25 | Mauna Kea Technologies and TaeWoong Medical USA Announce Exclusive Partnership to Accelerate Commercial Expansion in the U.S. in Pancreatic Cyst Management | 479 | Business Wire | Integrating Cellvizio into TaeWoong's portfolio of therapeutic devices to create the first fully integrated "imaging-to-therapy" solution for EUS-guided pancreatic care
Regulatory News:
Mauna... ► Artikel lesen | |
| 20.11.25 | Mauna Kea Technologies Receives NMPA Regulatory Approval in China for its Next-Generation Cellvizio Platform | 1.117 | Business Wire | NMPA approval obtained following a 3-year certification process Mauna Kea is now evaluating options to commercialize Cellvizio Gen 3 in China independently of the JV with Tasly
Regulatory... ► Artikel lesen | |
| 17.11.25 | XFRA 1MK: WIEDERAUFNAHME/RESUMPTION | 302 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 14.11.25 | Mauna Kea Technologies: €6 Million Raised To Strengthen Long Term Growth | 2 | pulse2.com | ||
| 14.11.25 | Mauna Kea Technologies Announces the Successful Completion of Its Financial Restructuring and €6M Capital Raise | 787 | Business Wire | 70% debt write-off, from €40M to €12M Remaining debt to be repaid over 10 years, with 90% between the end of 2029 and the end of 2035 Capital raise of €6.1M extending cash runway to the second... ► Artikel lesen | |
| 13.11.25 | XFRA 1MK: AUSSETZUNG/SUSPENSION | 569 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILMAUNA KEA TECHNOL.EO... ► Artikel lesen | |
| 13.11.25 | Mauna Kea Technologies Exits Safeguard Proceedings Following Court Approval of its Plan and Initiates Minimum €5M Capital Raise | 536 | Business Wire | Safeguard plan approved by judgment of the Paris Commercial Court on November 12, 2025 Launch of a reserved capital increase in the form of shares with attached warrants (ABSA) at a price of... ► Artikel lesen | |
| 06.11.25 | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 411 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 21.10.25 | Mauna Kea Technologies Announces It Has Secured Over €5M in Firm Subscription Commitments as Required for Its Capital Increase | 534 | Business Wire | New equity financing would provide the Company sufficient financial visibility to execute its strategic plan and achieve profitability The future exercise of share subscription warrants (BSA)... ► Artikel lesen | |
| 13.10.25 | Mauna Kea Technologies Reports Third Quarter 2025 Revenue Up +16% at Constant Exchange Rates | 373 | Business Wire | U.S. sales surge +31% at constant exchange rates, with continued acceleration over the year Commercial momentum highlighted by a doubling of U.S. system sales year-to-date Adding to U.S. commercial... ► Artikel lesen |
1 2 3 Weiter >>
50 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SERNOVA BIOTHERAPEUTICS | 0,095 | -1,56 % | Sernova Biotherapeutics: Sernova Biotherapeutics Announces Close of Non-Brokered Private Placement Financing | Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - March 24, 2026) - Sernova Biotherapeutics (TSX: SVA) (OTC Pink: SEOVF) (FSE: PSH0) ("Sernova" or the "Company"), a leading regenerative... ► Artikel lesen | |
| FAMICORD | 4,640 | -3,33 % | FAMICORD AG im Fokus - klare Schwäche, klare Linie | ||
| GERATHERM MEDICAL | 2,680 | -2,19 % | Geratherm Medical wechselt vom Börsensegment Scale in den Open Market | Die Geratherm Medical AG beendet zum 27. April 2026 die Einbeziehung ihrer Aktien in das Börsensegment Scale der Frankfurter Wertpapierbörse und wechselt ins Basic Board am Open Market. Die Börsennotierung... ► Artikel lesen | |
| PLUS THERAPEUTICS | 0,241 | +0,92 % | Plus Therapeutics Inc.: Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide May Reduce Leptomeningeal Metastases Healthcare Costs by 40% | ||
| MEDICLIN | 3,620 | +1,69 % | EQS-News: MEDICLIN AG: MEDICLIN lädt zur virtuellen Bilanzpressekonferenz 2026 ein | EQS-News: MEDICLIN AG
/ Schlagwort(e): Konferenz/Sonstiges
MEDICLIN lädt zur virtuellen Bilanzpressekonferenz 2026 ein
19.03.2026 / 15:24 CET/CEST
Für... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 0,001 | -100,00 % | Atossa Therapeutics Inc: Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives | Kathy Puyana Theall, M.D. and Adebola Giwa, M.D. bring deep expertise across oncology, rare diseases, and global clinical development to support advancement of Atossa's... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc. - 8-K, Current Report | ||
| SONOMA PHARMACEUTICALS | 2,350 | -100,00 % | Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Announces U.S. Retail Launch of Advanced Burn Relief Hydrogel in CVS and Walmart | BOULDER, CO / ACCESS Newswire / March 24, 2026 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader in hypochlorous acid (HOCl) technology, today announced the U.S. retail launch... ► Artikel lesen | |
| NOVACCESS GLOBAL | - | - | NovAccess Global Inc. - 10-K, Annual Report | ||
| VERU | 2,290 | 0,00 % | Veru Inc.: Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss | -- The Phase 2b study to assess enobosarm's ability to preserve lean mass, physical function, and bone as well as burn more fat to produce greater quality and quantity of weight loss in older patients... ► Artikel lesen | |
| LIFEWARD | 6,380 | +5,28 % | Lifeward Ltd.: Lifeward Reports Fourth Quarter and Full Year 2025 Financial Results | Advancing transformation into a diversified biomedical innovation company with a clear path to cash flow positive Oramed strategic transaction receives shareholder approval- Lifeward gains new... ► Artikel lesen | |
| LIGHT AI | 0,052 | -2,62 % | Light AI Inc: Light AI appoints Luna as CEO | ||
| EKSO BIONICS | 10,950 | +4,09 % | Applied Digital Corporation: Applied Digital to Spin Out Cloud Business, Proposes Business Combination with EKSO to Launch ChronoScale | DALLAS, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Applied Digital (NASDAQ: APLD), a designer, builder, and operator of high-performance, sustainably engineered data centers and colocation services for artificial... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 36,780 | +0,19 % | EQS-DD: Siemens Healthineers AG: Dorothea Simon, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
20.03.2026 / 16:23... ► Artikel lesen | |
| FRESENIUS | 44,510 | +0,77 % | EQS-DD: Fresenius SE & Co. KGaA: Sara Hennicken, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
20.03.2026 / 09:22... ► Artikel lesen |
Das Unternehmen MAUNA KEA TECHNOLOGIES kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 0,161 Euro und damit -1,82 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAUNA KEA TECHNOLOGIES finden Sie auf Wallstreet Online.